Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference By: Reunion Neuroscience Inc. via GlobeNewswire April 03, 2024 at 07:30 AM EDT MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA. The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile. Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression (NCT06342310). Details of the presentations are as follows: Podium Presentation Title: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum DepressionDate: Friday, April 12, 2024Time: 4:00-5:00 p.m. ETLocation: Westin Boston Seaport District: Harbor Ballroom I & II, Harbor LevelPresenter: Dr. Robert Alexander, Chief Medical Officer of Reunion Poster PresentationTitle: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum DepressionSession Date: Saturday, April 13, 2024Session Time: 3:45-5:15 p.m. ETPoster #: S150Location: Westin Boston Seaport District: Grand Ballroom, Concourse Level The poster will be available on Reunion’s website on Friday, April 12, 2024. About Reunion Neuroscience Inc. Reunion Neuroscience is committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for postpartum depression (PPD) and other underserved mental health disorders. The Company’s lead asset, RE104, a proprietary, potential best-in-class, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being evaluated as a potential treatment for postpartum depression, (NCT06342310), that could provide rapid symptom relief and durable efficacy. Reunion is actively investigating the use of RE104, which has a patent granted for exclusive rights for the composition of matter through 2042, in additional indications susceptible to being treated with a 5HT2A agonist molecule. For more information about the company, visit https://reunionneuro.com. Contact Sarah Sutton, Argot Partners(518) 932-3680sarah@argotpartners.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Reunion Neuroscience Inc. Announces Upcoming Presentations at the Anxiety and Depression Association of America (ADAA) 2024 Conference By: Reunion Neuroscience Inc. via GlobeNewswire April 03, 2024 at 07:30 AM EDT MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA. The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile. Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression (NCT06342310). Details of the presentations are as follows: Podium Presentation Title: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum DepressionDate: Friday, April 12, 2024Time: 4:00-5:00 p.m. ETLocation: Westin Boston Seaport District: Harbor Ballroom I & II, Harbor LevelPresenter: Dr. Robert Alexander, Chief Medical Officer of Reunion Poster PresentationTitle: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum DepressionSession Date: Saturday, April 13, 2024Session Time: 3:45-5:15 p.m. ETPoster #: S150Location: Westin Boston Seaport District: Grand Ballroom, Concourse Level The poster will be available on Reunion’s website on Friday, April 12, 2024. About Reunion Neuroscience Inc. Reunion Neuroscience is committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for postpartum depression (PPD) and other underserved mental health disorders. The Company’s lead asset, RE104, a proprietary, potential best-in-class, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being evaluated as a potential treatment for postpartum depression, (NCT06342310), that could provide rapid symptom relief and durable efficacy. Reunion is actively investigating the use of RE104, which has a patent granted for exclusive rights for the composition of matter through 2042, in additional indications susceptible to being treated with a 5HT2A agonist molecule. For more information about the company, visit https://reunionneuro.com. Contact Sarah Sutton, Argot Partners(518) 932-3680sarah@argotpartners.com
MORRISTOWN, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a venture backed clinical-stage biopharmaceutical company committed to pushing the boundaries of neuroscience, today announced that the clinical dataset from the Company’s Phase 1 study of its lead asset, RE104, will be presented in both a podium and poster at the Anxiety and Depression Association of America (ADAA) Conference taking place April 11-14, 2024, in Boston, MA. The presentations will highlight the Phase 1 findings on RE104, a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, a psilocybin-like compound. In a Phase 1 study, RE104 produced a psychedelic, psychoactive state similar in intensity and quality to psilocybin, but lasting only about half the time (3-4 hours) while demonstrating a similar, favorable safety profile. Reunion is evaluating RE104 in patients with underserved mental health disorders, beginning with postpartum depression (NCT06342310). Details of the presentations are as follows: Podium Presentation Title: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum DepressionDate: Friday, April 12, 2024Time: 4:00-5:00 p.m. ETLocation: Westin Boston Seaport District: Harbor Ballroom I & II, Harbor LevelPresenter: Dr. Robert Alexander, Chief Medical Officer of Reunion Poster PresentationTitle: RE104 – A Novel, Shorter-Acting Psychedelic for Postpartum DepressionSession Date: Saturday, April 13, 2024Session Time: 3:45-5:15 p.m. ETPoster #: S150Location: Westin Boston Seaport District: Grand Ballroom, Concourse Level The poster will be available on Reunion’s website on Friday, April 12, 2024. About Reunion Neuroscience Inc. Reunion Neuroscience is committed to pushing the boundaries of neuroscience to develop innovative, patented, FDA-approved serotonergic psychedelic therapeutic solutions for postpartum depression (PPD) and other underserved mental health disorders. The Company’s lead asset, RE104, a proprietary, potential best-in-class, serotonergic psychedelic compound and the only 4-OH-DiPT prodrug in clinical development, is being evaluated as a potential treatment for postpartum depression, (NCT06342310), that could provide rapid symptom relief and durable efficacy. Reunion is actively investigating the use of RE104, which has a patent granted for exclusive rights for the composition of matter through 2042, in additional indications susceptible to being treated with a 5HT2A agonist molecule. For more information about the company, visit https://reunionneuro.com. Contact Sarah Sutton, Argot Partners(518) 932-3680sarah@argotpartners.com